Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How do I Manage ILD/Pneumonitis with Verzenios® ▼ (abemaciclib) in Early Breast Cancer?
Persistent or recurrent Grade 2 toxicity was managed with dose suspension until toxicity resolved to baseline or Grade 1, while Grade 3 or 4 required discontinuation. Grade 1 or 2 did not require dose adjustment.
Interstitial Lung Disease (ILD)/Pneumonitis Monitoring and Dose Modification
ILD/pneumonitis was reported in patients receiving abemaciclib. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and treat as medically appropriate.1
Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.
Based on the severity of ILD/pneumonitis, abemaciclib may require dose modification. Permanently discontinue abemaciclib in patients with grade 3 or 4 ILD/pneumonitis.1